Skip to main content
Eligibility
for people ages 18 years and up
Location
at San Francisco, California
Dates
study started
Principal Investigator

Description

Summary

TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. The purpose of the study is to determine whether transarterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction.

Official Title

Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve

Keywords

Hepatocellular Carcinoma Chemoembolization Doxorubicin Liposomal doxorubicin

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Adult male or female patients, age 18 years of age or older
  2. Diagnosis of liver-only HCC based on European Association for the Study of the Liver(EASL) criteria (radiographic lesion appearance on contrast-enhanced CT or MRI, i.e.enhancement on early arterial phase, washout on portal venous phase with or without associated elevation of serum AFP level>200U/ml) or histologic confirmation of HCC diagnosis, whichever is applicable.
  3. UNOS stage T1, T2, or T3 disease.
  4. Candidates for liver transplantation (on vrc confcrienerd)accerdsr rforgawacceEASL) cr8sease.